Неразрешенная проблема: химиоиндуцированная полинейропатия

Закрыть метаданные

Рекомендуем статьи по данной теме:

Перспективные направления в лечении синдрома поликистозных яичников (обзор литературы). Проблемы репродукции. 2024;(3):94-104

Поздняя шизофрения и шизофреноподобный психоз с очень поздним началом. Журнал неврологии и психиатрии им. С.С. Корсакова. 2024;(7):32-40

Современное патогенетическое лечение редких демиелинизирующих заболеваний. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2024;(7-2):33-36

Ошибки в диагностике заболеваний спектра оптиконейромиелита приводят к неправильной терапии и ухудшению состояния пациентов. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2024;(7-2):96-100

Распространенная форма идиопатической атрофодермии Пазини—Пьерини у 17-летней пациентки. Клиническое наблюдение. Клиническая дерматология и венерология. 2024;(4):422-428

Современные аспекты этиопатогенеза, диагностики и лечения липедемы. Пластическая хирургия и эстетическая медицина. 2024;(3):86-92

Особенности выбора препаратов для купирования приступов мигрени и головной боли напряжения женщинами во время беременности. Российский журнал боли. 2024;(3):12-18

Церебролизин в превентивной терапии деменции у пожилых пациентов с синдромом мягкого когнитивного снижения: результаты трехлетнего проспективного сравнительного исследования. Журнал неврологии и психиатрии им. С.С. Корсакова. 2024;(9):51-59

Оценка качества оказания медицинской помощи пациентам с инфекциями, передаваемыми половым путем, в дерматовенерологических учреждениях Москвы на основании анализа медицинской документации. Клиническая дерматология и венерология. 2024;(5):503-509

Химиоиндуцированная полинейропатия — одна из значимых проблем в современной онкологии, резко ухудшая качество жизни пациентов, зачастую является причиной редукции и даже отмены лекарственной терапии. В обзоре представлены патофизиологические аспекты развития химиоиндуцированной полинейропатии, подробно описаны особенности диагностики лекарственной полинейропатии, факторы риска ее развития, возможности профилактики и лечения. Кроме единственного одобренного на данный момент ASCO дулоксетина, представлены результаты клинических исследований, подтверждающих сопоставимый с дулоксетином лечебный эффект центрального анальгетика со смешанным механизмом действия тапентадола.

Ключевые слова:

химиоиндуцированная полинейропатия

клиника

механизм развития

терапия

тапентадол

Авторы:

Абузарова Г.Р.

Московский научно-исследовательский институт им. П.А. Герцена — филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава России;
ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России

ORCID: 0000-0002-6146-2706

Сарманаева Р.Р.

ORCID: 0000-0002-0727-5758

Германова О.В.

Московский научно-исследовательский институт им. П.А. Герцена — филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава России

Дата поступления:

10.09.2024

Дата принятия в печать:

13.09.2024

Список литературы:

Brayall P, Donlon E, Doyle L, Leiby R, Violette K. Physical therapy-based interventions improve balance, function, symptoms, and quality of life in patients with chemotherapy-induced peripheral neuropathy: a systematic review. Rehabil Oncol. 2021;36(3):161-166. https://doi.org/10.1097/01.REO.0000000000000111
Papadopoulou M, Stamou M, Bakalidou D, Moschovos C, Zouvelou V, Zis P, Tzartos J, Chroni E, Michopoulos I, Tsivgoulis G. Non-pharmacological interventions on pain and quality of life in chemotherapy induced polyneuropathy: systematic review and meta-analysis. In Vivo. 2023;37(1):47-56. https://doi.org/10.21873/invivo.13053
De Iuliis F, Taglieri L, Salerno G, Lanza R, Scarpa S. Taxane induced neuropathy in patients affected by breast cancer: literature review. Crit Rev Oncol Hematol. 2015;96(1):34-45. https://doi.org/10.1016/j.critrevonc.2015.04.011
Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon M. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 2014;155(12):2461-2470. https://doi.org/10.1016/j.pain.2014.09.020
Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol. 2002;249(1):9-17. https://doi.org/10.1007/PL0000785
Тихонова О.А., Дружинин Д.С., Тынтерова А.М., Реверчук И.В. Современное представление о химиоиндуцированной полинейропатии (обзор литературы). Нервно-мышечные болезни. 2023;13(1):10-21. https://doi.org/10.17650/2222-8721-2023-13-1-10-21
Boyette-Davis J, Xin W, Zhang H. Dougherty PM. Intraepidermal nerve fiber loss corresponds to the development of taxol-induced hyperalgesia and can be prevented by treatment with minocycline. Pain. 2011;152(2):308-313. https://doi.org/10.1016/j.pain.2010.10.030
Hu LY, Mi WL, Wu GC, Wang YQ, Mao-Ying QL. Prevention and treatment for chemotherapy-induced peripheral neuropathy: therapies based on CIPN mechanisms. Curr Neuropharmacol. 2019;17(2):184-196. https://doi.org/10.2174/1570159X15666170915143217
Zhang H, Dougherty PM. Enhanced excitability of primary sensory neurons and altered gene expression of neuronal ion channels in dorsal root ganglion in paclitaxel-induced peripheral neuropathy. Anesthesiology. 2014;120(6):1463-1475. https://doi.org/10.1097/ALN.0000000000000176
Arguello F, Baggs RB, Frantz CN. A murine model of experimental metastasis to bone and bone marrow. Cancer Res. 1988;48(23):6876-6881.
Brown DC, Iadarola MJ, Perkowski SZ, Erin H, Shofer F, Laszlo KJ, Olah Z, Mannes AJ. Physiologic and antinociceptive effects of intrathecal resiniferatoxin in a canine bone cancer model. Anesthesiology. 2005;103(5):1052-1059. https://doi.org/10.1097/00000542-200511000-00020
Nassini R, Gees M, Harrison S, et al. Oxaliplatin elicits mechanical and cold allodynia in rodents via TRPA1 receptor stimulation. Pain. 2011;152(7):1621-1631. https://doi.org/10.1016/j.pain.2011.02.051
Sittl R, Lampert A, Huth T, Schuy ET, Link AS, Fleckenstein J, Alzheimer C, Grafe P, Carr RW. Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype Na(V)1.6-resurgent and persistent current. Proc Natl Acad Sci U S A. 2012;109(17):6704-6709. https://doi.org/10.1073/pnas.1118058109
Ta LE, Bieber AJ, Carlton SM, Loprinzi CL, Low PA, Windebank AJ. Transient receptor potential vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice. Mol Pain. 2010;6:15. https://doi.org//10.1186/1744-8069-6-15
Xiao W, Boroujerdi A, Bennett GJ, Luo ZD. Chemotherapy-evoked painful peripheral neuropathy: analgesic effects of gabapentin and effects on expression of the alpha-2-delta type-1 calcium channel subunit. Neuroscience. 2007;144(2):714-720. https://doi.org/10.1016/j.neuroscience.2006.09.044
Kawasaki Y, Xu ZZ, Wang X, et al. Distinct roles of matrix metalloproteases in the early- and late-phase development of neuropathic pain. Nat Med. 2008;14(3):331-336. https://doi.org/10.1038/nm1723
Wang XM, Lehky TJ, Brell JM, Dorsey SG. Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy. Cytokine. 2012;59(1):3-9. https://doi.org//10.1016/j.cyto.2012.03.027
Schäfers M, Sorkin L. Effect of cytokines on neuronal excitability. Neurosci Lett. 2008;437(3):188-193. https://doi.org/10.1016/j.neulet.2008.03.052
Butturini E, Carcereri de Prati A, Chiavegato G, Rigo A, Cavalieri E, Darra E, Mariotto S. Mild oxidative stress induces S-glutathionylation of STAT3 and enhances chemosensitivity of tumoural cells to chemotherapeutic drugs. Free Radic Biol Med. 2013;65:1322-1330. https://doi.org/10.1016/j.freeradbiomed.2013.09.015
Materazzi S, Fusi C, Benemei S, Pedretti P, Patacchini R, Nilius B, Prenen J, Creminon C, Geppetti P, Nassini R. TRPA1 and TRPV4 mediate paclitaxel-induced peripheral neuropathy in mice via a glutathione-sensitive mechanism. Pflugers Arch. 2012;463(4):561-569. https://doi.org/10.1007/s00424-011-1071-x
Musatov A, Robinson NC. Susceptibility of mitochondrial electron-transport complexes to oxidative damage. Focus on cytochrome c oxidase. Free Radic Res. 2012;46(11):1313-1326. https://doi.org/10.3109/10715762.2012.717273
Di Cesare Mannelli L, Zanardelli M, Failli P, Ghelardini C. Oxaliplatin-induced neuropathy: oxidative stress as pathological mechanism. Protective effect of silibinin. J Pain. 2012;13(3):276-284. https://doi.org/10.1016/j.jpain.2011.11.009
Doyle T, Chen Z, Muscoli C, et al. Targeting the overproduction of peroxynitrite for the prevention and reversal of paclitaxel-induced neuropathic pain. J Neurosci. 2012;32(18):6149-6160. https://doi.org/10.1523/JNEUROSCI.6343-11.2012
Sawicka E, Długosz A, Rembacz KP, Guzik A. The effects of coenzyme Q10 and baicalin in cisplatin-induced lipid peroxidation and nitrosative stress. Acta Pol Pharm. 2013;70(6):977-985.
Peters CM, Jimenez-Andrade JM, Kuskowski MA, Ghilardi JR, Mantyh PW. An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat. Brain Res. 2007;1168:46-59. https://doi.org/10.1016/j.brainres.2007.06.066
Luiz AP, MacDonald DI, Santana-Varela S, Millet Q, Sikandar S, Wood JN, Emery EC. Cold sensing by NaV1.8-positive and NaV1.8-negative sensory neurons. Proc Natl Acad Sci U S A. 2019;116(9):3811-3816. https://doi.org/10.1073/pnas.1814545116
MacDonald DI, Luiz AP, Iseppon F, Millet Q, Emery EC, Wood JN. Silent cold-sensing neurons contribute to cold allodynia in neuropathic pain. Brain. 2021;144(6):1711-1726. https://doi.org/10.1093/brain/awab086
Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol. 2002;249(1):9-17. https://doi.org/10.1007/PL00007853
Zajączkowska R, Kocot-Kępska M, Leppert W, Wrzosek A, Mika J, Wordliczek J. Mechanisms of chemotherapy-induced peripheral neuropathy. Int J Mol Sci. 2019;20(6):1451. https://doi.org/10.3390/ijms20061451
Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon MT. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 2014;155(12):2461-2470. https://doi.org/10.1016/j.pain.2014.09.020
Colvin LA. Chemotherapy-induced peripheral neuropathy: where are we now? Pain. 2019;160(Suppl. 1):S1-S10. https://doi.org/10.1097/j.pain.0000000000001540
Postma TJ, Heimans JJ, Muller MJ, Ossenkoppele GJ, Vermorken JB, Aaronson NK. Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol. 1998;9(7):739-744. https://doi.org/10.1023/a:1008344507482
Cho Y, Ruddy KJ, Lavoie Smith EM. Evaluation of chemotherapy-induced peripheral neuropathy. In: Lustberg M, Loprinzi C, eds. Diagnosis, management and emerging strategies for chemotherapy-induced neuropathy. Springer Cham; 2021;53-93. https://doi.org/10.1007/978-3-030-78663-2_3
Smith EM, Beck SL, Cohen J. The total neuropathy score: a tool for measuring chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum. 2008;35(1):96-102. https://doi.org/10.1188/08.ONF.96-102
Park SB, Kwok JB, Asher R, Lee CK, Beale P, Selle F, Friedlander M. Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial. Ann Oncol. 2017;28(11):2733-2740. https://doi.org/10.1093/annonc/mdx491
Calhoun EA, Welshman EE, Chang CH, Lurain JR, Fishman DA, Hunt TL, Cella D. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer. 2003;13(6):741-748. https://doi.org/10.1111/j.1525-1438.2003.13603.x
Le-Rademacher J, Kanwar R, Seisler D, et al. Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials. Support Care Cancer. 2017;25(11):3537-3544. https://doi.org/10.1007/s00520-017-3780-y
Li T, Timmins HC, Trinh T, et al. Patient-reported outcome measures in chemotherapy-induced peripheral neurotoxicity: defining minimal and clinically important changes. J Natl Compr Canc Netw. 2023;21(2):125-132.e3. https://doi.org/10.6004/jnccn.2022.7074.
Pérez C, Sánchez-Martínez N, Ballesteros A, Blanco T, Collazo A, González F, Villoria J. Prevalence of pain and relative diagnostic performance of screening tools for neuropathic pain in cancer patients: a cross-sectional study. Eur J Pain. 2015;19(6):752-761. https://doi.org/10.1002/ejp.598
Bennett M. The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs. Pain. 2001;92(1-2):147-157. https://doi.org/10.1016/S0304-3959(00)00482-6
Bechakra M, Nieuwenhoff MD, van Rosmalen J, Groeneveld GJ, Scheltens-de Boer M, Sonneveld P, van Doorn PA, de Zeeuw CI, Jongen JL. Clinical, electrophysiological, and cutaneous innervation changes in patients with bortezomib-induced peripheral neuropathy reveal insight into mechanisms of neuropathic pain. Mol Pain. 2018;14:1744806918797042. https://doi.org/10.1177/1744806918797042
Boyette-Davis J, Xin W, Zhang H, Dougherty PM. Intraepidermal nerve fiber loss corresponds to the development of taxol-induced hyperalgesia and can be prevented by treatment with minocycline. Pain. 2011;152(2):308-313. https://doi.org/10.1016/j.pain.2010.10.030
Boyette-Davis JA, Hou S, Abdi S, Dougherty PM. An updated understanding of the mechanisms involved in chemotherapy-induced neuropathy. Pain Manag. 2018;8(5):363-375. https://doi.org/10.2217/pmt-2018-0020
Mezzanotte JN, Grimm M, Shinde NV, Nolan T, Worthen-Chaudhari L, Williams NO, Lustberg MB. Updates in the treatment of chemotherapy-induced peripheral neuropathy. Curr Treat Options Oncol. 2022;23(1):29-42. https://doi.org/10.1007/s11864-021-00926-0
Salehifar E, Janbabaei G, Hendouei N, Alipour A, Tabrizi N, Avan R. Comparison of the efficacy and safety of pregabalin and duloxetine in taxane-induced sensory neuropathy: a randomized controlled trial. Clin Drug Investig. 2020;40(3):249-257. https://doi.org/10.1007/s40261-019-00882-6
Avan R, Janbabaei G, Hendouei N, Alipour A, Borhani S, Tabrizi N, Salehifar E. The effect of pregabalin and duloxetine treatment on quality of life of breast cancer patients with taxane-induced sensory neuropathy: a randomized clinical trial. J Res Med Sci. 2018;23:52. https://doi.org/10.4103/jrms.JRMS_1068_17
Galiè E, Villani V, Terrenato I, Pace A. Tapentadol in neuropathic pain cancer patients: a prospective open label study. Neurol Sci. 2017;38(10):1747-1752. https://doi.org/10.1007/s10072-017-3035-1
Sansone P, Giaccari LG, Aurilio C, Coppolino F, Passavanti MB, Pota V, Pace MC. Comparative efficacy of tapentadol versus tapentadol plus duloxetine in patients with chemotherapy-induced peripheral neuropathy (CIPN): a randomized non-inferiority clinical trial. Cancers (Basel). 2022;14(16):4002. https://doi.org/10.3390/cancers14164002
Streckmann F, Zopf EM, Lehmann HC, May K, Rizza J, Zimmer P, Gollhofer A, Bloch W, Baumann FT. Exercise intervention studies in patients with peripheral neuropathy: a systematic review. Sports Med. 2014;44(9):1289-1304. https://doi.org/10.1007/s40279-014-0207-5
Cunningham JE, Kelechi T, Sterba K, Barthelemy N, Falkowski P, Chin SH. Case report of a patient with chemotherapy-induced peripheral neuropathy treated with manual therapy (massage). Support Care Cancer. 2011;19(9):1473-1476. https://doi.org/10.1007/s00520-011-1231-8
Klafke N, Bossert J, Kröger B, et al. Prevention and treatment of chemotherapy-induced peripheral neuropathy (CIPN) with non-pharmacological interventions: clinical recommendations from a systematic scoping review and an expert consensus process. Med Sci (Basel). 2023;11(1):15. https://doi.org/10.3390/medsci11010015
Izgu N, Ozdemir L, Bugdayci Basal F. Effect of aromatherapy massage on chemotherapy-induced peripheral neuropathic pain and fatigue in patients receiving oxaliplatin: an open label quasi-randomized controlled pilot study. Cancer Nurs. 2019;42(2):139-147. https://doi.org/10.1097/NCC.0000000000000577
Kanzawa-Lee GA, Larson JL, Resnicow K, Smith EML. Exercise effects on chemotherapy-induced peripheral neuropathy: a comprehensive integrative review. Cancer Nurs. 2020;43(3):E172-E185. https://doi.org/10.1097/NCC.0000000000000801
Gewandter JS, Chaudari J, Ibegbu C, et al. Wireless transcutaneous electrical nerve stimulation device for chemotherapy-induced peripheral neuropathy: an open-label feasibility study. Support. Care Cancer. 2019;27(5):1765-1774. https://doi.org/10.1007/s00520-018-4424-6
Armstrong T, Almadrones L, Gilbert MR. Chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum. 2005;32(2):305-311. https://doi.org/10.1188/05.ONF.305-311

Закрыть метаданные